Immutep Limited has announced promising results from its INSIGHT-003 trial, presented at the ESMO Congress 2025, showcasing a novel combination of eftilagimod alfa (efti) with KEYTRUDA and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback